Health Canada Approves of DENOZA™, a Denosumab Biosimilar
May 5, 2026
Apotex Inc., a Canadian based global pharmaceutical company announced that Health Canada has approved DENOZA™ (denosumab injection), a denosumab biosimilar, for its authorized indications.
These include the treatment of postmenopausal women with osteoporosis at high risk for fracture and the treatment of osteoporosis in men at high risk for fracture. DENOZA is also authorized for the remaining indications of the reference biologic.
Health Canada Approves of DENOZA™, a Denosumab Biosimilar
May 5, 2026
Latest News Health Canada Approves of DENOZA™, a Denosumab Biosimilar May 5, 2026 Apotex Inc., a Canadian based global pharmaceutical company announced that Health Canada has approved DENOZA™ (denosumab injection), […]
Latest News Positive Outcome for BMD Testing in Ontario April 30, 2026 At Osteoporosis Canada, we are aware that the April 1, 2026 updates to the Schedule of Benefits included […]
April 24, 2026 Contributors: Dr. Adrian Lau, Dr. Heather McDonald-Blumer, Dr. Laëtitia Michou, Dr. Claudia Gagnon, Dr. Zahra Bardai , Dr. Vithika Sivabalasundaram, Sarah Rydahl, Dr. Shirine Usmani, As of April […]
